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Abstract: A novel electrochemical sensing method was devised for the first time to detect 
plasma cortisol, a potential psychological stress biomarker, in human immunodeficiency virus 
(HIV)-positive subjects. A miniaturized potentiostat (reconfigured LMP91000 chip) interfaced 
with a microfluidic manifold containing a cortisol immunosensor was employed to demonstrate 
electrochemical cortisol sensing. This fully integrated and optimized electrochemical sensing 
device exhibited a wide cortisol-detection range from 10 pg/mL to 500 ng/mL, a low detection 
limit of 10 pg/mL, and sensitivity of 5.8 µA (pg mL)-1, with a regression coefficient of 0.995. 
This cortisol-selective sensing system was employed to estimate plasma cortisol in ten samples 
from HIV patients. The electrochemical cortisol-sensing performance was validated using an 
enzyme-linked immunosorbent assay technique. The results obtained using both methodolo-
gies were comparable within 2%–5% variation. The information related to psychological stress 
of HIV patients can be correlated with disease-progression parameters to optimize diagnosis, 
therapeutic, and personalized health monitoring.
Keywords: psychological stress, personalized health care, cortisol, HIV, electrochemical 
immunosensing, miniaturized sensing device
Introduction
Progression of human immunodeficiency virus (HIV) infection leads to life-threatening 
diseases, such as acquired immunodeficiency syndrome (AIDS).1–3 Progress in HIV 
infection is characterized as a function of immune system impairments wherein 
various stress factors, such as cortisol, play a significant role in diseases progression 
and diagnosis.1–7 HIV infection activates the hypothalamic production and secre-
tion of corticotropin-releasing hormone. This in turn causes the release of cytokine 
inflammatory response against viral infection, which stimulates the hypothalamus–
pituitary–adrenal axis. This immunomodulation generates psychological stress that 
activates the corticotropic axis. HIV patients exhibit increased glucocorticoid-receptor 
expression and reduced substrate-binding affinity, which increases plasma cortisol and 
correlates with adrenocorticotropic hormone levels, affecting adrenal sufficiency.1,2 
The hypothesis related to cortisol secretion and its relation with sensitized behavior 
in HIV-infected patients is illustrated in Figure 1.8
However, there is no clear evidence to prove the existence of a correlation between 
cortisol levels and HIV-infection stages.9 Higher plasma cortisol levels have been 
observed more in untreated HIV-positive patients compared to treated patients.5 Besides 
this, a negative correlation between CD4 cell count and plasma cortisol levels has also 
been reported.2,5,8 It appears that cortisol contributes to suppression of beneficial activity 
of T-helper (Th)-1 cytokines in favor of Th2 cytokines (eg, IL-4, IL-6, and IL-10), 
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and hence leads to greater HIV progression. Recently, many 
studies have reported the significance of cortisol detection 
and its correlation with different diseases.3,7,10–13 Therefore, 
diurnal cortisol detection in the laboratory and at the point 
of care (POC) has a great impact in monitoring sensitized/
altered human behavior.11,12 Diurnal cortisol circadian rhythm 
is affected by schedule/activity and psychological/emotional 
stress of individuals. Cortisol abnormalities depress the 
immune system and lead to Cushing’s disease, Addison’s 
disease, and posttraumatic disorder.11,12 The enzyme-linked 
immunosorbent assay (ELISA) is the most reliable classical 
method to detect cortisol levels in patient samples. This method 
is limited to the laboratory, due to its requirements of longer 
measurement time, complex sample processing, expert man 
power, and sensing limitation to high concentrations (ng/mL 
or more). Therefore, cortisol detection in patients at the clinic 
or POC is in demand to understand diurnal behavioral pat-
terns of individual subjects.14
Due to its salient features, such as fast, selective, and 
sensitive detection, an electrochemical cortisol-immuno-
sensing methodology is being rapidly adopted for corti-
sol detection at the pg/mL level.11–13 The introduction of 
nano/microelectrodes, nanostructured sensing materials, 
microelectronics, and miniaturized sensing transducers 
in sensor fabrication have been shown to improve device 
performance.11,12,15–19 The integration of a cortisol sensor 
with a microfluidic system and a miniaturized potentiostat 
(M-P) has been reported to monitor cortisol with reduced 
form factors.11,18,20 Further, efforts are being made to develop 
these sensing systems at POC levels for personalized health 
monitoring.14,18,21–23 Electrochemical immunosensors based on 
self-assembled monolayers (SAMs) and nanostructures have 
been reported to detect cortisol, but their application in real 
sample analysis is currently limited.16–18 Therefore, there is an 
urgent need to establish an electrochemical sensing protocol 
for detecting cortisol in desired fluids, such as plasma, blood, 
saliva, urine, and interstitial fluid, of patients at the POC.
In this current research, we illustrate the integration of 
an electrochemical sensing device capable of performing 
cyclic voltammetry (CV) to detect plasma cortisol levels 
in HIV-positive patients. We validated the performance of 
the developed method by ELISA, and sensing performance 
was in correlation within 2%–5% variation. Therefore, in 
conclusion we say that this method can be adopted as a part 
of stress management, specifically for personalized health 
care monitoring of HIV-positive patients.
Materials and methods
Fabrication of electrochemical 
immunosensor
Dithiobis(succinimidyl propionate) (DTSP), sodium borohy-
dride (NaBH
4
), monoclonal anticortisol antibody (anti-C
ab
), 
cortisol, and other chemicals were purchased from Sigma-
Aldrich, and were used without any further purification. 
Phosphate-buffered saline (PBS) solution (10 mM, pH 7.4) 
was prepared by dissolving one PBS tablet in 200 mL 
HIV–HPA axis
Psychological stress
cortisol monitoring
Behavioral mechanism,
diagnostics and treatment
HIV disease progression
CD4, T-cell decline, AIDS diagnosis
AIDS-defining illness, AIDS-related death
Interlinking of psychological stress, sensitized
behavior, and its relation with virus progress
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O
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H
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Figure 1 schematic illustration of hPa axes in hIV progression. In cases of hIV, there is impaired adrenal reverse and more peripheral glucocorticoid excess.
Abbreviations: HPA, hypothalamus–pituitary–adrenal; HIV, human immunodeficiency virus; CRH, corticotropin-releasing hormone; ACTH, adrenocorticotropic hormone; 
AIDS, acquired immunodeficiency syndrome.
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cortisol detection in hIV-positive patients
of deionized (DI) water and used to prepare the anti-C
ab
 
(1 mg/mL) and cortisol concentrations.
The detailed experimental process related to electrochemi-
cal cortisol sensor fabrication was described in our previous 
publications in detail.18,24 We employed an electrochemically 
cleaned interdigitated gold microelectrode (IDE-Au; chamber 
volume ~5 µL, electrode width and electrode gap 10 µm), 
which were dispersed in a 2 mg/mL solution of DTSP (reduced 
using NaBH
4
 [10 mg/mL in DI water]) for 2 hours to prepare 
SAMs. The unbound DTSP particles on the electrode surface 
were washed with acetone, and final washing was done with 
DI water. For electrochemical immunosensor fabrication, 
5 µL of anti-C
ab
 (1 mg/mL) was covalently immobilized (for 
2 hours) onto a DTSP-SAM/IDE-Au electrode via amide-bond 
formation between the amine group of antibodies and the reac-
tive succinimidyl group of the DTSP. Anti-C
ab
/DTSP-SAM/
IDE-Au bioelectrodes were washed using PBS (pH 7.4, 10 
mM) to remove any unbound molecules. Ethanolamine (EA, 
5 µL of 2 mg/mL) was immobilized on the anti-C
ab
/DTSP/
IDE-Au bioelectrode for 10 minutes to bind the nonspecific 
site of the immunoelectrode, followed by washing using 
DI water. Finally, EA/anti-C
ab
/DTSP/IDE-Au immunoelec-
trodes were stored in a refrigerator at 4°C when not in use.
Design of LTCC-based microfluidic 
manifold
A low temperature co-fired ceramic (LTCC) microfluidic 
architecture was utilized, which consisted of two micro-
channels. Both channels were connected to a reaction 
chamber placed on top of a biosensor chip. These channels 
were used for sample-in and waste-out processes using a 
three-way solenoid fluidic valve. During sensing, the wash-
ing step is crucial to avoid contamination and nonspecific 
moieties from the sensor surface. To obtain optimum wash-
ing efficiency, a computational fluid dynamic approach via 
Comsol Multiphysics® software was used to characterize 
fluid-flow profiles. The details of the design optimization 
of the LTCC microfluidic manifold were published in our 
previous report.18 The LTCC microfluidic chip consists of 
three layers of green tape (DuPont 951). The bottom layer 
is a reaction chamber (5 mm diameter and volume of 10 µL) 
that interfaces with the sensor. The middle layer has an inlet 
and outlet microchannels for the navigation of sample/buffer/
waste. The top layer covers the microchannels and ports for 
incorporating fluidic connectors. Green tapes were patterned 
using a computer-controlled 10.6 µm CO
2
 laser with a spot 
size of 35 µm. Further, the patterned tape was aligned to be 
laminated using an isostatic hot press (Phi-Tulip) at 150°C 
for 15 minutes at 3,000 psi pressure. The aligned laminated 
green tape layers were fused to the LTCC through heating 
at 850°C in the presence of oxygen. Tygon tubing was con-
nected at an inlet and outlet port of the microfluidic manifold 
via polydimethylsiloxane (Dow Corning). The fluids were 
introduced into the device via a programmable two-syringe 
pump network (New Era Pumps). A fabricated microfluidic 
device containing a biosensor chip was integrated with an 
acrylic fixture for portability. The final device was connected 
with an M-P for electrochemical measurement.18
During measurement, 10 µL of each sample was intro-
duced in the inlet channel at a flow rate of 10 µL/min. The 
sample was incubated on immunosensor electrodes (static 
condition) for 30 minutes for the completion of the antigen–
antibody reaction. Further, the washing buffer solution (30 µL) 
was then introduced into the reaction chamber (10 µL/min for 
3 minutes) to remove unbound moieties. For electrochemical 
experiments, 5 µL of measurement buffer (PBS, pH 7.4) con-
taining 5 mM Fe(II)/Fe(III) as redox moieties was allowed to 
flow in the reaction chamber. Solenoid three-way valves (Lee) 
were utilized for the successful flow of samples and buffer.
Design of miniaturized potentiostat
A schematic illustration of the electrochemical cortisol-
immunosensing protocol, preparation of the immunosensor, 
architecture of the LTCC-based microfluidic manifold, 
reconfigured M-P chip (LMP9100) for electrochemical 
measurement, and comparison of M-P-obtained CV curve of 
IDE with a conventional potentiostat is shown in Figure 2. 
The details related to the preparation of the M-P have been 
explained in our previous work.14 In brief, the LMP91000 
board was procured from Texas Instruments and reconfig-
ured to design an M-P capable of performing full-range 
CV measurement using a three-electrode system. For CV 
measurements using the LMP91000, an external central 
processing unit with SensorAFE Designer software was 
connected with a USB communication feature. A Beagle-
Bone microcontroller unit was added to make the device 
portable. To enable the communication, the LMP91000EVM 
was powered and controlled by the microcontroller via the 
I2C interface.
To achieve three-electrode-based electrochemical measure-
ments, we removed the two-wire jumper pin and connected a 
J_MENB jumper to enable manual operation mode. A recon-
figured LMP91000EVM generated an output voltage propor-
tional to the current flowing through the working electrode. 
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This voltage was provided by the transimpedance amplifier at 
the output stage. The acquisition of the signal response of the 
potentiostat was sent back to the microcontroller through the 
serial peripheral interface of the ADC161S626 analog digital 
converter (embedded on the LMP91000EVM). On applying 
optimized programming, the LMP91000EVM performed CV 
as a function of varying scan-rate potential in the range from 
-0.6 V to 0.6 V. The output voltage of the LMP91000EVM 
is proportional to the cell current. This can be obtained by 
plugging the output voltage of the LMP91000EVM in the 
transimpedance-amplifier transfer-function equation, taking 
into consideration the parameters set for the CV measurement 
using the equation:
 I
V V
TIAout
out INT Z
gain
=
–
–  (1)
The electrochemical performance of the Au-IDE based on 
CV using the M-P was comparable with the results obtained 
using a Metrohm Autolab potentiostat, thus validating M-P 
performance.16
electrochemical measurement
CV-based electrochemical measurements using the M-P at 
a scan rate of 50 mV/s in 5 µL of PBS (pH 7.4) containing 
5 mM (Fe[CN]
6
)3-/4- as redox moieties in a potential range 
from -0.6 to 0.6 V were conducted to characterize sensor 
fabrication and to detect cortisol concentrations. To retain 
high biological activity of biomolecules, a pH of 7.4 for the 
PBS was chosen. This was attributed to the fact that this is 
the optimum pH selected for electrochemistry of immunosen-
sors. An EA/anti-C
ab
/DTSP-SAM/IDE-Au electrochemical 
immunosensor was used to detect cortisol in plasma samples 
of HIV-positive patients.
Plasma sample collection of hIV patients
Blood donors were apprised of this study, and their con-
sent was obtained consistent with the policies of Florida 
International University (FIU) and the National Institutes 
of Health (NIH). The study protocol was approved by the 
institutional review board of FIU. HIV-infected patients 
were recruited from the Borinquen Health Care Center, 
Miami. Patients were males and females. All vital clinical 
information, ie, race, sex, drug therapy, and CD4 levels 
of each available HIV patient (n=10), obtained from 
the hospital is summarized in Table 1. The identities of 
all the subjects recruited were kept confidential. Blood 
from the donors to be processed as plasma was directly 
drawn into blood-collection tubes containing the antico-
agulant K2 ethylenediaminetetraacetic acid (BD; Fisher 
Scientific; catalog number 366643). Following collection, 
all plasma samples were centrifuged immediately for 15 
minutes at 5,000 g at 4°C, and supernatants were carefully 
collected.
Plasma cortisol samples were stored at -20°C to maintain 
their biological activity. All the samples were defrosted to 
room temperature for further use to detect cortisol concen-
tration using electrochemical immunosensors and ELISA. 
A cortisol (human) ELISA kit was procured form Abnova 
Assays, and a standard protocol was adopted to estimate 
plasma cortisol. In brief, 50 µL of 1:3 PBS diluted plasma 
cortisol samples of all patients were used for ELISA 
measurements.
Results and discussion
electrochemical studies of cortisol sensor
The reconfigured LMP91000-based M-P chip was utilized 
to characterize electrochemical immunosensor fabrication 
and cortisol-sensing performance. The electrochemical 
Table 1 Patient demographics
Patient 
identification
Age  
(years)
Sex (ethnicity) HIV status (year  
of diagnosis)
Antiretroviral  
drugs
CD4 level
358 26 Male (african-american) Positive (1998) Yes 363
261 35 Male (african-american) Positive (2010) Yes 624
398 41 Male (caucasian) Positive (2004) Yes 235
377 44 Male (african-american) Positive (2005) Yes 134
250 45 Male (african-american) Positive (1996) Yes 671
256 46 Male (african-american) Positive (2010) Yes 326
486 48 Male (african-american) Positive (1999) Yes 700
202 50 Male (african-american) Positive (1995) Yes 237
487 43 Female (african-american) Positive (2002) Yes 654
405 49 Female (african-american) Positive (1993) Yes 608
Abbreviation: HIV, human immunodeficiency virus.
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response study of the IDE-Au electrode (curve a), DTSP-
SAM/IDE-Au electrode (curve b), anti-C
ab
/DTSP-SAM/
IDE-Au immunoelectrode (curve c), EA/anti-C
ab
/DTSP-
SAM/IDE-Au immunoelectrode (curve d), and response 
change after adding cortisol on the immunosensor surface 
(curve e) is shown in Figure 3A. A detailed explanation of 
sensor fabrication, characterization, and optimization of 
operation parameters has been described in our previous 
publications.18,24 In brief, fabrication of DTSP-SAM onto 
electronically conducting IDE-Au hinders electron transport 
from electrolytes to the working electrode, due to the insulat-
ing nature of SAMs. This confirms the preparation of SAMs 
onto Au via thiol bonding. The electrochemical response-
current magnitude of DTSP-SAM/IDE-Au further decreased 
after immobilizing the anti-C
ab
 via amide bonding. The pres-
ence of insulating anti-C
ab
 on the surface caused hindrance 
in electron transport, thus confirming immobilization. The 
nonbinding sites of the anti-C
ab
/DTSP-SAM/IDE-Au immu-
noelectrode were blocked using EA. This also decreased 
the electrochemical response current, due to a reduction 
in electron transport from electrolytes to the IDE. The 
scan-rate-dependent CV of electrodes and bioelectrodes was 
also studied. A linear relationship between the magnitude of 
the electrochemical response current and the square root of 
the scan rate was observed (data not shown). This proved that 
the electrode surface was a linear diffusion-driven process. A 
linear relationship was also observed between the scan rate 
and potential differences, revealing facile electron transport 
from electrolytes to the working electrode surface.
Electrochemical cortisol-immunosensing studies of the 
EA/anti-C
ab
/DTSP-SAM/IDE-Au sensor were performed as 
a function of cortisol concentration (10 pg/mL to 500 ng/mL) 
using M-P, as described in the Materials and methods sec-
tion. Five microliters of each cortisol concentration was 
incubated on the sensor surface. An incubation time of 
30 minutes was used to achieve optimum binding of the 
antibody and cortisol. Prior to electrochemical measure-
ment, all immunoelectrodes were washed using 30 µL 
of PBS (pH 7.4) to remove the unbound cortisol. All the 
measurements were made in triplicate, and an average 
of these was used for cortisol-concentration estimation. 
A reduction in electrochemical response current was observed 
after the addition of each cortisol concentration. This was 
attributed to the insulating nature of the immunocomplex 
formed between anti-C
ab
 and cortisol. This barrier layer inhib-
ited the electron transport from electrolytes to the IDE-Au.
A calibration curve was plotted between the magnitude 
of current response and logarithm of cortisol concentration 
(Figure 3B). A linear-dependent relation was observed, which 
followed the equation:
Y = 1.6 × 10-5 + 5.8 × 10-6⋅ log (Cortisol concentration):  
R=0.995 (2)
The electrochemical cortisol immunosensor developed by 
us exhibited a wide linearity from 10 pg/mL to 500 ng/mL 
(on logarithmic scale), a low detection limit of 10 pg/mL, 
and a sensitivity of 5.8 µA (pg mL)-1, with a regression 
Figure 3 Electrochemical stepwise characterization of cortisol immunosensor and cortisol sensing calibration curve.
Notes: (A) CV response study of IDE-Au (curve a) electrode, DTSP-SAM/IDE-Au (curve b) electrode, anti-C
ab
/DTSP-SAM/IDE-Au immunoelectrode (curve c), EA/anti-
c
ab
/DTSP-SAM/IDE-Au immunoelectrode (curve d), and response change after adding cortisol on sensor surface (curve e). (B) A calibration curve was obtained using an 
electrochemical cortisol sensor as a function of cortisol concentrations (10–500 pg/mL) on a logarithmic scale.
Abbreviations: CV, cyclic voltammetry; IDE, interdigitated electrode; DTSP, dithiobis(succinimidyl propionate); SAM, self-assembled monolayer; EA, ethanolamine; anti-C
ab
, 
anticortisol antibody; SD, standard deviation.
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coefficient of 0.995. The studies related to the selectivity 
and stability of this immunosensor have been discussed in 
our previous publications.18,24 The electrochemical response 
current of immunosensors using prostate specific antigen 
(100 pg/mL), neuron-specific enolase (100 pg/mL), Epi-
dermal growth factor receptor (100 pg/mL), bovine serum 
albumin + cortisol (100 pg/mL), and cortisol (100 pg/mL) 
exhibited maximum change in the case of cortisol only. A 
variation of electrochemical response of ~1%–2% in case of 
interferents and ~14% with respect to cortisol was observed. 
This confirmed the selectivity of our developed cortisol 
immunosensor (data not shown).24 CV studies related to the 
shelf life of the EA/anti-C
ab
/DTSP-SAM/IDE-Au immuno-
electrode at intervals of 1 week revealed that the electro-
chemical sensor exhibited a response within 5% variation 
and stability for 28 days (data not shown).24
electrochemical immunosensing 
of plasma cortisol
For plasma cortisol analysis, the EA/anti-C
ab
/DTSP-SAM/
IDE-Au immunosensor was utilized for detecting plasma 
cortisol concentrations in HIV-positive patients. A plasma 
sample (5 µL) from each patient was incubated on the 
cortisol-immunosensor surface for 30 minutes. Further, the 
sensor surface was washed using 30 µL of PBS (pH 7.4) to 
remove unbound plasma particles. The magnitude of the 
electrochemical response current of the EA/anti-C
ab
/DTSP-
SAM/IDE-Au immunosensor was found to change after the 
addition of each plasma sample. The established calibration 
curve (Figure 3A) was used to estimate final cortisol con-
centration. All measurements were made in triplicate, and 
an average value was computed to estimate plasma cortisol 
concentration (Table 2). The obtained sensing performance 
as validated with ELISA technique is presented in Table 2.
Plasma cortisol detection using elIsa
The ELISA technique was performed using a 96-well titer 
plate with respect to six known concentrations (20, 50, 100, 
200, 400, and 800 ng/mL) to establish a calibration curve 
(Figure 4A). A detection limit of 1.5 ng/mL, a detection 
range of 20–800 ng/mL, a sensitivity of 50 ng/mL (Iab, 
intensity of absorbance), along with a regression coefficient 
of 0.989 and a standard deviation of ±1.06, were achieved 
using an ELISA kit. The sensing-performance outcomes of 
both techniques are summarized in Table 3. The obtained 
calibration curve was used to measure unknown plasma 
cortisol concentration in HIV-positive patient samples. 
All measurements were made in triplicate, and an average 
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Figure 4 ELISA calibration curve to estimate plasma cortisol concentration and comparisons of plasma cortisol concentrations of HIV positive patients estimated using ELISA 
and cV method.
Notes: (A) Calibration plot obtained using ELISA techniques to detect plasma cortisol concentrations in HIV-positive patient. (B) a comparison of plasma cortisol of cocaine 
using hIV patients using elIsa and cV methods.
Abbreviations: ELISA, enzyme-linked immunosorbent assay; HIV, human immunodeficiency virus; CV, cyclic voltammetry; B%/Bo. mean absorbance of standards/means 
absorbance of negative control; au, arbitrary unit.
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value was utilized to estimate the final concentration, as 
shown in Table 2. A comparison of plasma cortisol level 
estimated using ELISA and electrochemical immunosensor 
is presented in Figure 4B.
The transduction techniques, ie, mode of output response, 
of ELISA (I
Iab
) and the electrochemical immunosensor (A) 
are different in nature of principle. Thus, obtained outcomes 
were in different magnitudes for each concentration. To 
establish a correlation for comparison between both tech-
niques, the electrochemically detected cortisol concentrations 
were normalized by a factor of 2.4. Both techniques showed 
comparable results with 2%–5% variation, thus confirming 
the validation of the electrochemical cortisol-immunosensing 
protocol. However, in our previous study, a correlation fac-
tor of 2.2 was established to validate the results obtained 
using an electrochemical EA/anti-Cab/DTSP-SAM/IDE-Au 
immunosensor and ELISA to detect salivary cortisol.24 This 
difference is due to the physiological variation of biological 
fluids, eg, saliva has free cortisol, and plasma also contains 
bound cortisol, ie, corticosteroid-binding globulin.
An established, well-correlated, and validated electrochemi-
cal immunosensing protocol enables the quantification of plasma 
cortisol, and has the potential to detect cortisol in other biologi-
cally relevant fluids, such as saliva and interstitial fluids.
Conclusion
In this work, we detected plasma cortisol levels in 
HIV-positive patient samples using an electrochemical immu-
nosensing device. The investigated device, consisting of an 
M-P chip interfaced with an LTCC microfluidic manifold, 
demonstrated cortisol detection at the pg/mL level with a 
sensitivity of 5.8 µA (pg mL)-1. The plasma cortisol of HIV-
positive patients was also estimated successfully using the 
ELISA technique. The obtained results were in good cor-
relation (2%–5%) with those obtained using the investigated 
electrochemical sensor. This confirmed the validation of the 
developed method. Efforts are being made to coordinate with 
clinics and hospitals to increase the sample volume of HIV-
positive patients. Higher sample volumes will be of use to 
understand the relation of diurnal cortisol variation of HIV 
patients with virus-infection progress. Such obtained infor-
mation or findings can be correlated with clinical diagnostics 
of HIV patients for personalized health monitoring and to 
decide on therapeutics.
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